Status:
COMPLETED
OStéopontin as a Marker Of StenoSIS - OSMOSIS
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Stenosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Our hypothesis is that a plasma protein named osteopontin (OPN) could serve as a biological predictive marker of acute AVF dysfunction. In several scientific studies, plasma OPN was correlated with co...
Eligibility Criteria
Inclusion
- Patients under a social security scheme
- Written informed consent obtain
- 18 years old or older
- end-stage renal failure disease with 3 months dialysis minimum on a native arteriovenous fistula
- Non-inclusion Criteria:
- Subject under juridicial protection
- Pregnant or lactating women
- Subject already enrolled in a clinical trial involving a drug or an implantable medical device
Exclusion
- Withdrawal of consent
- Investigator or sponsor decision
Key Trial Info
Start Date :
February 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 17 2019
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT03270358
Start Date
February 8 2018
End Date
September 17 2019
Last Update
November 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice - Service de chirurgie vasculaire
Nice, France